Evidence map›Paper›PMID 33318003›Full record

ArticleAntimicrobial agents and chemotherapy2021

A Second-Generation Fungerp Analog, SCY-247, Shows Potent

Sherman Chu, Lisa Long, Thomas S McCormick, Katyna Borroto-Esoda, Stephen Barat, Mahmoud A Ghannoum

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. The novel second-generation triterpenoid SCY-247 maintainsAntimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sherman ChuDepartment of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
Lisa LongDepartment of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
Thomas S McCormickDepartment of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
Katyna Borroto-EsodaScynexis Inc., Jersey City, New Jersey, USA.
Stephen BaratScynexis Inc., Jersey City, New Jersey, USA.
Mahmoud A GhannoumDepartment of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA mag3@case.edu.ORCID 0000-0002-8833-7323
Scynexis (United States) · USUniversity Hospitals of Cleveland · USCase Western Reserve University · USPacific Northwest University of Health Sciences · US

Funding

Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infectionR01AI172944 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Mahmoud A Ghannoum, Thomas S Mccormick · 2023 to 2026
$2.5M
Identification of effective SCY-078 analogues targeting C. aurisR21AI143305 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI GHANNOUM, MAHMOUD A · 2019 to 2020
$441k
NIAID NIH HHS R01 AI172944NIAID NIH HHS R21 AI143305
6 · The paper itself

Abstract

Echinocandins are a first-line therapy for

Indexed as

Candida albicansCandidiasisAnimalsAntifungal AgentsDisease Models, AnimalGlycosidesMiceMicrobial Sensitivity TestsAntifungal AgentsGlycosidescandidiasisfungerpibrexafungerpSCY-247triterpenoid classβ-(1,3)-d-glucan

Identifiers

PMID33318003
PMCPMC8092520
OpenAlexW3112277311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.